(PMVP)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
| Name | Position |
|---|---|
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board |
| Dr. Binh Vu Ph.D. | Senior Vice President of Drug Discovery & CMC |
| Dr. David H. Mack Ph.D. | Co-Founder, CEO, President & Director |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Dr. Marc Fellous M.D. | Senior VP and Head of Clinical Development & Medical Affairs |
| Mr. Michael Carulli | Chief Financial Officer |
| Mr. Robert Ticktin J.D. | General Counsel, COO & Company Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-03-06 | 8-K | pmvp-20260306.htm |
| 2025-11-12 | 8-K | pmvp-20251112.htm |
| 2025-09-10 | 8-K | d90438d8k.htm |
| 2025-08-07 | 8-K | pmvp-20250807.htm |
| 2025-06-09 | 8-K | d57209d8k.htm |
| 2025-05-09 | 10-Q | pmvp-20250331.htm |
| 2025-04-25 | DEFA14A | ny20041194x2_defa14a.htm |
| 2025-03-03 | 8-K | pmvp-20250303.htm |
| 2024-11-25 | CORRESP | filename1.htm |
| 2024-11-20 | S-3 | d868133ds3.htm |
| Mr. Tim Smith M.B.A. | Senior VP and Head of Corporate Development & Investor Relations |
| Ms. Crystal Zuckerman | Vice President of Human Resources |
| Ms. Laura De Leon | VP & Head of Clinical Development Operations |